Abstract

Background

Bacterial infections are frequent triggers for diabetic ketoacidosis. In this context, delayed antibiotic treatment is associated with increased morbidity and mortality. Unnecessary administration of antimicrobial therapy might however, also negatively impact the prognosis. The usefulness of sepsis markers in diabetic ketoacidosis has not been assessed. Thus, we sought to investigate diagnostic performances of clinical and biological sepsis markers during diabetic ketoacidosis.

Methods

In this monocentric retrospective cohort study, all consecutive episodes of diabetic ketoacidosis (defined as pH ≤ 7.25, glycaemia > 300 mg/dL and presence of ketones) admitted in intensive care unit were included. A proven bacterial infection was defined as bacteriological documentation on any bacterial sample. Clinical (presence of fever: temperature > 38 °C and presence of hypothermia: temperature < 36 °C) and biological markers (whole blood count, neutrophils count, neutrophils-to-lymphocytes count ratio and procalcitonin), recorded at admission, were compared according to the presence or absence of a proven bacterial infection.

Results

Between 2011 and 2018, among 134 episodes of diabetic ketoacidosis, 102 were included (91 patients). Twenty out of 102 were infected. At admission, procalcitonin (median: 3.58 ng/mL vs 0.52 ng/mL, p < 0.001) and presence of fever (25% vs 4%, p = 0.007) were different between episodes with and without proven bacterial infection in both univariate and multivariate analysis. Whole blood count, neutrophils count, neutrophils-to-lymphocytes count ratio and presence of hypothermia were not different between both groups. The diagnostic performance analysis for procalcitonin revealed an area under the curve of 0.87 with an optimal cutoff of 1.44 ng/mL leading to a sensitivity of 0.90 and a specificity of 0.76. Combining procalcitonin and presence of fever allowed to distinguish proven bacterial infection episodes from those without proven bacterial infection. Indeed, all patients with procalcitonin level of more than 1.44 ng/mL and fever had proven bacterial infection episodes. The presence of one of these 2 markers was associated with 46% of proven bacterial infection episodes. No afebrile patient with procalcitonin level less than 1.44 ng/mL had a proven bacterial infection.

Conclusion

At admission, combining procalcitonin and presence of fever may be of value to distinguish ketoacidosis patients with and without proven bacterial infection, admitted in intensive care unit.

Details

Title
Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis
Author
Blanchard, Florian 1   VIAFID ORCID Logo  ; Charbit, Judith 2 ; Van der Meersch Guillaume 1 ; Popoff, Benjamin 3 ; Picod Adrien 4 ; Cohen, Regis 5 ; Chemouni, Frank 6 ; Gaudry Stephane 7 ; Bihan Helene 8 ; Cohen, Yves 9 

 AP-HP, Paris 13 University, Sorbonne Paris Cité, Medical-Surgical Intensive Care Unit, Avicenne University Hospital, Bobigny, France 
 AP-HP, Paris 13 University, Sorbonne Paris Cité, CRNH-IdF, Department of Endocrinology, Diabetology, Metabolic Disease, Avicenne University Hospital, Bobigny, France 
 Rouen University Hospital, Department of Anesthesiology and Critical Care, Rouen, France (GRID:grid.41724.34) 
 AP-HP, Paris 13 University, Sorbonne Paris Cité, Medical-Surgical Intensive Care Unit, Avicenne University Hospital, Bobigny, France (GRID:grid.41724.34) 
 Delafontaine Hospital, Department of Endocrinology, Saint-Denis, France (GRID:grid.41724.34) 
 Gustave Roussy, Médecine Intensive Réanimation, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388) 
 AP-HP, Paris 13 University, Sorbonne Paris Cité, Medical-Surgical Intensive Care Unit, Avicenne University Hospital, Bobigny, France (GRID:grid.14925.3b); Sorbonne University, INSERM, Remodeling and Repair of Renal Tissue, UMR S1155, Tenon Hospital, Paris, France (GRID:grid.14925.3b) 
 AP-HP, Paris 13 University, Sorbonne Paris Cité, CRNH-IdF, Department of Endocrinology, Diabetology, Metabolic Disease, Avicenne University Hospital, Bobigny, France (GRID:grid.14925.3b) 
 AP-HP, Paris 13 University, Sorbonne Paris Cité, Medical-Surgical Intensive Care Unit, Avicenne University Hospital, Bobigny, France (GRID:grid.14925.3b) 
Publication year
2020
Publication date
Dec 2020
Publisher
Springer Nature B.V.
e-ISSN
21105820
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2404533592
Copyright
© The Author(s) 2020. corrected publication 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.